Navigation Links
Pharmexa A/S (DK) - Long lasting immune response and survival to,RAS vaccine

Summary: Follow-up RAS data presented at ASCO

HORSOLM, Denmark, June 4, 2007-Professor Trond Buanes today gave a presentation titled "RAS peptide vaccination in resected pancreatic cancer patients - persistence of anti tumour response and long term survival" at ASCO's (American Society of Clinical Oncology) annual cancer meeting.

A follow-up study of 23 resected pancreatic cancer patients immunized in the period from 1995 to 1998 with two different peptide vaccines targeting the RAS mutation found in most instances of pancreatic cancer indicates that a long lasting immune response is possible following immunization with a peptide vaccine. Five patients that showed an immune response to the vaccine were still alive in 2006, i.e. up to 10 years after the operation. Further analysis showed that the immune system in three of these patients still remembered the RAS vaccination.

The RAS vaccines are owned by Pharmexa. In addition, Pharmexa owns a number of other proprietary cancer peptide vaccines, including GV1001 which is in phase III clinical trials.

Hørsholm, June 4, 2007

Jakob Schmidt Chief Executive Officer

Additional information: Jakob Schmidt, Chief Executive Officer, telephone +45 4516 2525 Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45 4060 2558

Note to editors: Pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer, bone degeneration and Alzheimer's disease, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide vaccine that has entered phase III trials in pancreatic cancer and phase II trials in liver cancer, and HIV and hepat itis vaccines in phase I/II. Collaborative agreements include H. Lundbeck, Innogenetics, ImmunoVaccine Technologies and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 105 people and is listed on the Copenhagen Stock Exchange under the trading symbol PHARMX.

http://hugin.info/131680/R/1130841/211128.pdf


'"/>




Related medicine technology :

1. Pharmexa A/S (DK) - Pharmexa presents data from influenza program
2. Xanthus Presents Novel Approach for Autoimmune Disease Reversal with Symadex
3. Cellerant Therapeutics Reversed Autoimmune Disease in Lupus Mice with Transplant of Purified Donor Blood Stem Cells
4. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
5. Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases
6. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
7. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
8. Apollo develops needle-free topical vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... , May 20, 2016 ... Pipeline Review, H1 2016" market research report with ... Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ... news and press releases. It also reviews key ...
(Date:5/19/2016)... -- A new report published by Allied ... Forecasts, 2015 -2022, projects that the world medical imaging ... CAGR of 5.1% from 2015 to 2022. X-ray imaging ... revenue-generating segment throughout the forecast period. North ... market share in 2015, and is expected to dominate ...
(Date:5/19/2016)... , May 19, 2016 The equities ... is always abounding of surprises is without doubt the Healthcare ... ahead of today,s trading session: Alkermes PLC (NASDAQ: ... IDEXX Laboratories Inc. (NASDAQ: IDXX ), and Atossa ... your complimentary alerts at: http://www.activewallst.com/ ...
Breaking Medicine Technology:
(Date:5/23/2016)... ... May 23, 2016 , ... NYDNRehab, a New York City-based physical therapy ... the first time this type of technology, which was developed by world-renowned researcher Dr. ... in New York. , With over 10 million sport injuries per year ...
(Date:5/23/2016)... ... , ... ComplianceOnline, the leading governance, risk and compliance advisory network with over ... 15 and 16, 2016 in San Diego, CA. The two day summit steered by ... of the largest gatherings of medical device companies, suppliers, professionals and experts in 2016. ...
(Date:5/23/2016)... , ... May 23, 2016 ... ... security executive networking and relationship-marketing firm, announced today that nominations will be ... Security Executive® (ISE®) Northeast Awards. , Awards include the Information Security Executive® ...
(Date:5/23/2016)... ... 2016 , ... Hadley Institute for the Blind and Visually ... or visually impaired, announces the election of Julie S. Tye as its next ... of Trustees retained Morris & Berger, a firm specializing in non-profit executive searches, ...
(Date:5/23/2016)... ... May 23, 2016 , ... Octo Consulting Group, a leading provider ... is proud to announce they have recently won two awards from AFCEA International. ... Business of the Year. Additionally, Octo VP of Civilian Affairs, Naina Leo, was named ...
Breaking Medicine News(10 mins):